Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on MEDIGENE AG. We currently have 7 research reports from 1 professional analysts.
|20Dec16 06:30||GNW||Medigene announces outlicensing of AAVLP technology|
|16Dec16 06:30||GNW||Medigene participates at four national and international conferences in January 2017|
|06Dec16 10:21||GNW||Medigene AG to be included in TecDAX Index|
|22Nov16 06:30||GNW||Medigene appoints Dr. Thomas Taapken as Chief Financial Officer|
|16Nov16 06:30||GNW||Medigene highlights a new approach for neoantigen-specific TCRs at Neoantigen Summit 2016 in Boston|
|10Nov16 06:30||GNW||Medigene reports its results for the first nine months of 2016|
|04Nov16 06:30||GNW||Medigene participates at six national and international conferences|
Frequency of research reports
Research reports on
Strategic alliance validates TCR technology
05 Oct 16
Medigene has announced an alliance with bluebird bio, a prominent T-cell immunology company. It is Medigene’s first commercial partnering agreement based on its proprietary T-cell receptor (TCR) technology platform. The collaboration will seek to identify four TCR therapeutic candidates against four targets. This is a positive development as it validates Medigene’s TCR technology and makes use of technological synergies to develop new immuno-oncology products, which could prove beneficial. Importantly, it does this while retaining all rights for its proprietary TCR development programme and TCR library. We have increased our valuation to €233m (vs €219m), as we have rolled the model forward to an estimated Q3 position and included the upfront payment.
Expansion of platform technology
26 Jul 16
Medigene has announced that it has expanded its TCR platform technology with the grant of a US patent focused on a method for identifying T-cell antigens. This demonstrates Medigene’s continued advancement of its TCR technology, including providing a new source for potential TCR candidates and establishing a more efficient method for identifying tumour-specific antigens. We maintain our rNPV-based valuation at €214m, or €10.8 per share, with upside expected as it executes its clinical strategy.
Co-operation agreement for Phase I IIT TCR trial
05 Jul 16
Medigene has announced it has entered into a co-operation agreement to conduct a Phase I investigator-initiated TCR therapy trial (IIT), with grant funding, in patients with relapsed/refractory multiple myeloma. This is an important step forward in the process of bringing its TCR therapy to patients, a potentially transformational approach to treating certain cancers. The final aspect is the regulatory approval for the trial, to which Medigene is contributing. We expect the Phase I trial to initiate at end 2016/early 2017. We maintain our rNPV-based valuation at €214m, or €10.8 per share, with upside expected when the Phase I trial is initiated.
Continuing to progress its clinical pipeline
19 May 16
Medigene’s Q1 results continue to underpin its transformation to a cancer immunotherapy-focused company. Progress across its clinical pipeline continues to create further focus on clinical development and future commercialisation. Alongside management changes, this indicates that the company is executing its strategy. It is well funded, with a net cash position of €46.3m (Q116).
An advancing immunotherapies programme
06 Apr 16
Medigene is well funded, with a net cash position of €46.8m (FY15). There is a clear strategy in place to advance both its DC vaccine programmes and TCR programme with the funds. We expect newsflow in the near term from its most advanced technology (DC vaccines) in Phase I/II studies for AML and prostate cancer, and the start of the first clinical study with its promising TCR technology. Our rNPV-based valuation remains at €216m.
Recent deals enable greater focus on the core
08 Feb 16
Recent non-core, business-related newsflow has proved highly beneficial to Medigene. The full and final transference of EndoTAG-1 rights to SynCore and the sale of its Catherex subsidiary to Amgen for $10.5m (40% to Medigene) tidies up its legacy pipeline and IP assets, while providing a decent revenue stream. Medigene’s core focus remains on its immuneoncology franchise, and we look forward to significant progress in 2016. Our rNPV-based valuation increases to €216m or €10.98 per share.
The Monthly January 2017
09 Jan 17
Despite all the hullaballoo of the Brexit vote and the subsequent election of Donald Trump as the next US President, the UK stock market prospered last year, especially in the latter few months of 2016. The combination of a depreciating currency – making $ earnings more valuable in relative terms - and the Trump emphasis on infrastructure expenditure drove the stock market higher
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare
N+1 Singer - Small-cap quantitative research - Momentum screen refresh + 10 focus stocks
12 Jan 17
We have refreshed our momentum style screen for the first time since inception on 26 July 2016. As before, the screen selects the 25 stocks exhibiting the most extreme momentum characteristics, according to our measurement method. From these we have selected 10 to focus on. Since inception the screen has underperformed both the main small-cap and micro-cap indices against a background of generally rising momentum. We have noted a subset of the basket, where decelerating momentum at the time of measurement appears correlated with significant share price falls since selection. We shall monitor this factor with the new screen, albeit there are only two such stocks showing this pattern, namely Lamprell (not rated) and Gear4music (not rated).
N+1 Singer - Morning Song 16-01-2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
Panmure Morning Note 17-01-2017
17 Jan 17
Dechra has announced a trading update for the half year to 31 December 2016 and, given the tone and confidence of the company’s prelims statement and presentation in September, investors are unlikely to be surprised that the underlying business and acquisitions continue to ‘perform well’. Ahead of a full update of our investment thesis we place our recommendation and forecasts under review, but note that the core business continues to progress well in spite of the obvious distraction of the recent M&A programme. We look towards interims on 27 February 2017.